B+
Bull case
20%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
KRMD
KORU MedicalANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
KORU combines record Q2 revenue, improving profitability, a large home-infusion opportunity, and strategic investments in connected monitoring and higher-volume oncology molecules. The refined outlook supports a cautiously constructive operating case [#SEC-8K-2026-08-05].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Analyst consensus, estimate revisions, options positioning, short interest, employee sentiment, and post-earnings price attribution are unavailable.
Momentum
96
Value
42
Sentiment
88
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.75 · Bull $5.50 · Bear $2.40Analysis 2026-09-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $6.25
Why
Momentum96 · Δ7d -
Value42 · Δ7d -0.0
Sentiment88 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Analyst consensus, estimate revisions, options positioning, short interest, employee sentiment, and post-earnings price attribution are unavailable.
- • Benefits from the multi-year supply agreement are not quantified.
- • International growth is expected to moderate, the Phesgo pathway was withdrawn, and the replacement oncology strategy remains unproven.
Catalyst clock
2026-12-31
Execution against refined FY2026 outlook
Lead driver: Sentiment · See AI snapshot
Momentum
96
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.4
Sentiment
88
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 96.0 / Value 41.9 / Sentiment 87.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-04. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$3.75
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$155.14M
Beta
0.44
Shares Out
46.17M
P/E (TTM) · Derived
-58.8
P/S (TTM)
6.60
P/FCF (TTM) · Derived
202.41
Rev YoY
+18.2%
EPS YoY
-213.3%
Gross Margin
+60.7%
Op Margin
-3.7%
Net Debt
-$5.38M
Current Ratio
2.72
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data